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Summary
Background: Molecular serum markers that can identify early reversible osteoarthritis (OA) in horses are lacking.
Objectives: We studied serum concentrations of a novel cartilage oligomeric matrix protein (COMP) neo-epitope in horses subjected to short-term
exercise and with acute lameness. The effects of circadian rhythm and age were also evaluated.
Study design: Longitudinal studies in healthy horses and cross-sectional comparison of lame and non-lame horses.
Methods: Sera were collected from five horses before and after short-term interval exercise and during full-day box rest. Sera from 32 acutely lame
horses were used to evaluate age-related effects. Independent samples from control horses (n = 41) and horses with acute lameness (n = 71) were
included. COMP neo-epitope concentrations were analysed using custom-developed inhibition ELISAs validated for equine serum. The presence of
COMP neo-epitope was delineated in healthy and osteoarthritic articular cartilage with immunohistochemistry.
Results: COMP neo-epitope concentrations decreased after speed training but returned to baseline levels post-exercise. No correlations between age
and serum COMP neo-epitope concentrations were found (r = 0.0013). The mean (s.d.) serum concentration of COMP neo-epitope in independent
samples from non-lame horses was 0.84  0.38 lg/mL, and for lame horses was 5.24  1.83 lg/mL (P<0.001). Antibodies against COMP neo-epitope
did not stain normal articular cartilage, but intracytoplasmic staining was found in superficial chondrocytes of mild OA cartilage and in the extracellular
matrix of moderately osteoarthritic cartilage.
Main limitations: ELISA was based on polyclonal antisera rather than a monoclonal antibody. There is a sex and breed bias within the groups of
horses, also it could have been of value to include horses with septic arthritis and tendonitis and investigated joint differences.
Conclusions: This COMP neo-epitope can be measured in sera, and results indicate that it could be a biomarker for pathologic fragmentation of
cartilage in connection with acute joint lameness.
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Introduction
Osteoarthritis (OA), a slow and progressive low-grade inflammatory disease
[1,2], affects the athletic horse at an early age [3]. Possible monitoring of
early biochemical cartilage degradation is a prerequisite to alter
progression from a reversible to an irreversible event [4]. Imaging
biomarkers are traditionally used to diagnose and study OA progression.
However, different imaging techniques are limited in distinguishing normal
tissue from early disease [5]. This has shifted focus towards biochemical
fluid (‘wet’) markers [4]. Immunological assays are most commonly used to
investigate OA in humans [6] and horses [7,8]. Specific antibodies that
detect matrix components and proteinases in sera, urine and synovial
fluids from horses have been used for enzyme-linked immunosorbent
assay (ELISA) [4]. However, available biomarker assays are unable to
distinguish pathologic fragmentation from normal cartilage turnover;
instead, biomarkers of cartilage matrix changes must exclusively detect
pathological degradation. Several studies [9–11] have shown that cartilage
oligomeric matrix protein (COMP) in synovial fluid and serum is a promising
biomarker of OA-associated cartilage destruction in horses.
COMP, a major noncollagenous, 524-kDa, homo-pentameric protein, is
present in articular cartilage where it binds collagen type II [12] and IX [13],
cross-bridging the collagen network. Synovial fluid COMP concentrations
decrease in young horses during long-term training and in OA joints [14].
However, elevated concentrations were observed in equine joints with
osteochondral fractures [15]. These studies utilised ELISA with polyclonal
antibodies that detect the native molecule and degraded monomers and
further cleaved fragments. Recently [16], we analysed a unique COMP neo-
epitope in synovial fluids from horses and found that its concentration
increased in animals with acute lameness compared to that in horses with
chronic lameness and in non-lame joints.
Our aim was to develop an ELISA that can measure this neo-epitope in
serum and delineate if short-term training, circadian rhythm, age of the
horse and acute lameness affect its concentration. We hypothesised that
the neo-epitope could be measured in serum, and that its concentration is
not affected by sampling time, short-term training or animal age. We also
predicted that concentrations would increase with acute lameness similar
to that observed for synovial fluid [16].
This is an open access article under the terms of the Creative Commons Attribution
License, which permits use, distribution and reproduction in any medium, provided
the original work is properly cited.
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Materials and methods
Horses after short-term exercise and box rest
Serum samples were collected from five Standardbred (STB) horses before
and after a short-term interval exercise session (Table 1). Five horses were
also sampled several times during a 24-h box rest [17,18]. The horses
belonged to the Swedish Academy of Trotting and Thoroughbred Racing,
Sweden. They were used for the education of apprentices and professional
race trainers, and performed a simulated 2,140 m trotting race or interval
training once a week. Lameness examination was not performed on these
horses before exercise sessions or box rest. On days when no intensive
exercise was performed, horses spent the morning hours in paddocks or
were subjected to lighter exercise. The study took place between April and
June 1995.
Exercise tests: In the morning (08:00–12:00), exercise tests were
performed on a field track. For this, the horses trotted five 500 m intervals
at a speed of 11.1  0.2 m/s (heart rate ~200 beats/min; heart-rate
recorder)a. After each interval, the horses returned to the start in a slow
trot. This return trip took 2–4 min, depending on whether or not blood
samples were collected. Exercise started with a warm-up in slow trot
(14 min). The horses returned to the stable in slow trot which took 13 min
immediately after the last interval. An intravenous catheter was inserted
into a jugular vein, in the evening before the exercise test, and flushed with
heparinised saline (0.2% heparin) overnight and with isotonic saline between
samplings. Blood samples were collected at rest 1), after warm-up 2),
before and after interval number four (time points 3 and 4), before and
after interval number five (time points 5 and 6) and 15, 20, 30, 40 and
50 min after the last exercise interval (time points 7, 8, 9, 10 and 11). A final
blood sample (time point 12) was collected before the next feeding the
same day (1–4.5 h post-exercise).
Circadian sampling: Five STB horses were used for blood sampling every
hour for 24 h to determine the resting profile of each animal (Table 1).
Additional blood samples were taken every 15 min for 1 h after the 17.30
and 05.30 meals were provided. Blood samples were taken via a catheter
(Intranule [2.0 9 105 mm])b introduced into one of the jugular veins. An
extension tube was attached to the catheter to facilitate blood sampling.
At 03:30, several horses were lying down; therefore, this sample was not
collected.
Horses of different ages
Blood samples were collected from 32 acutely lame horses of different
ages that underwent a lameness examination at the University Animal
Hospital (Uppsala, Sweden) (Table 1).
Independent samples from control and lame horses
The inclusion criteria for the control horses (n = 14) recruited in the study
were: considered to be sound by their owner, fit for breeding evaluation
test including no radiological changes in their tarsal joints. Additional
healthy stallions of the Icelandic horse breed (n = 27) with no radiological
changes in their tarsal joints were included. These stallions were predicted
to be fit for the riding test, included in a breeding evaluation, by their
owners.
The inclusion criteria for the lame horses were: presented with acute
lameness (duration not more than 2 weeks according to the owner)
originating from one or more joints, and verified by a flexion test reaction,
and that intra-articular anaesthesia reduced the pain by up 75–100%. The
horses were recruited from Kungsbacka Horse Clinic (n = 29), Gothenburg,
Sweden and University Animal Hospital (n = 42), Uppsala, Sweden (Table 1).
All samples were stored in aliquots in 80°C to prevent unnecessary
freezing and thawing.
Neo-epitope ELISA
The neo-epitope at the N-terminal part of one COMP fragment, containing
five amino acids from the native COMP sequence (SGPTH), was detected in
media at day 3 after interleukin-1b stimulation in vitro [19].
An inhibition ELISA was developed to quantify the COMP neo-epitope in
serum, and was modified based on a previous protocol [16]. In short,
NUNC platesc were coated with 4.0 lg/mL peptide (sequence, SGPTHEGVC)
diluted in 0.1 mol/L carbonate buffer (pH 9.6), and incubated at 4°C
overnight. A serial dilution of 5.0 lg/mL of peptide (sequence
SGPTHEGVGMA) in 10 mmol/L PBS with 0.6% BSA and 0.8% SDS was used
as the calibration curve (range = 5–0.078 lg/mL). Serum samples were
diluted 1:10 in PBS with 0.89% SDS. Standard and serum samples were
incubated in 96-well Sterilin platesc at 25°C overnight. On the second day,
primary anti-neo-epitope of COMP antibody (diluted in PBS with 1% BSA
and 4% triton-X-100) was added to the plates, which were incubated for
80 min at 25°C. NUNC plates were washed and blocked with 200 lL PBS
with 1% BSA and 0.1% tween for 1 h, at 25°C. Next, 100 lL was transferred
from the plates to NUNC plates and incubated for 1 h at 25°C. After
incubation, NUNC plates were washed and secondary antibody (goat anti-
rabbit IgG H&L [HRP]) (Ab97051)d, diluted 1:20,000 in PBS with 1% BSA and
0.1% tween, was added. The plates were incubated for 1 h at 25°C and
then washed six times and incubated with substrate (Substrate Reagent
Pack DY999)e for approximately 8 min at 25°C. Stop solution (1 mol/L
H2SO4) was added, and the absorbance was measured at 450 nm
(SpectraMaxPlus 384)f. The intra-assay precision was determined by
analysing 20 replicates of one sample with a medium concentration of the
COMP neo-peptide. The inter-assay precision was determined through the
analysis of 20 replicates from one sample on two occasions.
The detection limit for the assay was determined by analysing 20
replicate samples at varying concentrations.
Quality control samples consisting of pooled sera from 20 horses were
run for every ELISA to ensure inter-assay stability.
Immunohistochemistry-based cartilage sampling
Articular cartilage was from morphologically (macroscopically and
microscopically) classified joints; one normal (carpal) sample and two with
TABLE 1: Age, sex, breed and joint distribution of horses included in studies of a novel serum concentrations of cartilage oligomeric matrix
protein (COMP) neo-epitope
Age Sex
Breed Joints
Horses N
Mean  s.d.
(min–max) (n = M, G, S) SWH STB Ponies
Icelandic
horses PRE Coffin1 Fetlock2 Carpal Tarsal Stifle
Short-term exercise study 5 7.0  2.0 (5–10) (0, 5, 0) 5 NA
24 h box-rest study 5 7.4  1.9 (5–10) (0, 5, 0) 5 NA
Age correlation study 32 11  4.7 (3–20) (10, 21, 1) 21 2 8 1 7 28 13 9 0
Acutely lame horses 71 9.2  4.6 (2–20) (28, 34, 4) 35 20 11 3 2 15 45 52 9 2
Non-lame horses 41 7.9  4.6 (5–20) (14, 0, 27) 41 NA
N, number of horses; Min, minimum; Max, maximum; Sex: M, mare; G, gelding; S, stallion; NA, not applicable; SWH, Swedish Warmblood horses; STB,
Standardbred horses; PRE, Pura Raza Espa~nola.
1
Distal interphalangeal joint.
2
Metacarpal/phalangeal/metatarsal/phalangeal joints.
Equine Veterinary Journal 51 (2019) 674–680 © 2019 The Authors. Equine Veterinary Journal published by John Wiley & Sons Ltd on behalf of EVJ Ltd. 675
S. Ekman et al. Serum concentrations of a COMP neo-epitope in horses
OA lesions (carpal and fetlock) were sampled at necropsy. Articular
cartilage was immersed in 10% buffered formaldehyde, dehydrated,
embedded in paraffin and tissue sections were stained with a polyclonal
antibody against the COMPg neo-epitope (dilution 1:1000) and native COMP
(Ab74524)d (dilution 1:800) [16]. Briefly, specimens were sectioned and
mounted onto slides, deparaffinised, rehydrated and washed in phosphate-
buffered saline (PBS; 0.01 mol/L phosphate, 0.15 mol/L NaCl, pH 7.4).
Endogenous peroxidase activity was quenched with 3% hydrogen peroxide
in PBS. Nonspecific binding was blocked with 2% normal goat serum
(X0907)h, prior to incubation with antiserum. After rinsing in PBS, sections
were incubated with horseradish peroxidase (HRP)-conjugated secondary
antibodies (K5007) and visualisation (Real EnVision™ Detection System
k5007 [ready-to-use kit])h was performed using the colour developer 3,
3-diaminobenzidine. For negative (isotype) controls, the primary antibody
was substituted with nonimmune rabbit serum (X0936)h at the same
dilution used for the primary antibody. The sections were evaluated by
light microscopyi.
Data analysis
Values for COMP neo-epitope in serum are presented as means and
standard deviations (s.d.). Second-degree polynomials in time points were
fitted to data simultaneously for both short-term exercise and box-rested
COMP values (series) with interaction terms for series and time, and series
and squared times. A linear relationship between age and serum
concentration of COMP neo-epitope was investigated by calculating the
correlation coefficient with a corresponding P value. This was performed
parametrically (Pearson) and P≤0.05 was considered significant. The
difference in means between lame and healthy horses was significantly
different from 0 as tested by a two-sample t test. The diagnostic
performance of the ELISA that discriminated lame horses from healthy
animals was evaluated by receiver operating characteristic (ROC) curve
analysis [20]. Statistical calculations were performed using SAS-procedure
mixed (SAS version 9.4)j and ROC test was performed in GraphPad Prism
(version 5.01 for Windows)k.
Results
ELISA
The ELISA for serum COMP neo-epitope was determined to be valid with a
detection limit of 0.156 lg/mL and inter-assay variation of 10.6% and intra-
assay variation of 10.5%.
Effects of short-term exercise
The mean (s.d.) serum concentrations of COMP neo-epitope at time
points 1 and 12 were 2.25 lg/mL (0.12) and 2.17 lg/mL (0.19),
respectively, during short-term exercise (Fig 1). However, the curve was
convex with an initial decrease that was followed by an increase up to the
last time point; hence, the coefficient for squared time was positive and
statistically significant. The equation for values for exercised horses was
y = 2.52810.2467t + 0.01614t2, with P = 0.003 for time and P = 0.003
for time-squared.
Circadian effects
The mean (s.d.) serum concentrations of COMP neo-epitope at time
points 1 and 30 (the last time point) were 3.14 (0.68) lg/mL and 2.89
(0.95) lg/mL respectively. The coefficients for time and time-squared
were not statistically significant; hence, no differences were identified
during box rest (Fig 2).
The equation for values for box-rested horses was y = 3.1143 +
0.002851t4.79* 106 t2, with P = 0.9 for time and P>0.9 for squared
times.
Age-related effects
The mean (s.d.) age of the 32 horses was 11 (4.7) years, with a range
of 3–20 years, and the serum concentration of COMP neo-epitope was 4
(0.96) lg/mL. The correlation coefficient for age and serum concentration
was r = 0.0013 and the corresponding P value (>0.9) indicated no
correlation between these parameters (Fig 3).
Independent samples from non-lame horses and
acutely lame horses
Forty-one healthy horses, mean age (s.d.) 7.9  4.6 and 71 lame horses,
age 9.2  4.6, were included. The mean (s.d.) serum concentrations of
COMP neo-epitope in independent samples were 0.84  0.38 lg/mL and
5.24  1.83 lg/mL for non-lame and lame horses respectively (P<0.001;
Fig 4). The area under the ROC curve was 0.99 (standard error, 0.0006) and
the 95% confidence interval was 0.99–1.00, which was significantly different
from 0.5 (P<0.0001).
Immunohistochemistry analysis
The two OA joints were characterised as mild, with only focal superficial
lesions of the articular cartilage, and moderate, with an area in the radial
facet of cartilage fraying, cleft formations (superficial and middle layers) and
erosions. The normal articular cartilage presented extracellular matrix (ECM)
staining with antibodies against native COMP in all cartilage layers (Fig 5a);
however, no COMP neo-epitope staining (Fig 5b) was found. The articular
cartilage with mild lesions showed staining with antibodies against native
COMP in the ECM of all cartilage layers; however, fainter staining was
observed in middle and deep layers compared to that in the superficial
layer (Fig 5c). Antibodies against COMP neo-epitope showed
intracytoplasmic staining of the superficial chondrocytes in cluster
formations (chondrones) surrounding small areas of acellular ECM
(chondronecrosis) (Fig 5d). Adjacent single chondrocytes within the
superficial zone displayed intracytoplasmic and ECM staining (Fig 5d).
Articular cartilage with moderate OA lesions showed intense staining in
the ECM of all cartilage layers, with antibodies against native COMP (Fig 5e).
Antibodies against the COMP neo-epitope stained the chondrocytes in
cluster formations and the ECM of superficial and middle articular cartilage
layers (Fig 5f). The pericellular matrix surrounding the chondrones did not
show immunostaining (Fig 5f). Controls did not result in staining in normal
and OA articular cartilages.
Discussion
Assays to detect OA joints have been developed that detect matrix
components such as collagens, aggrecan and COMP and inflammatory
cytokines in serum and synovial fluid. However, these biomarkers reflect
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Fig 1: Mean (s.d.) serum concentration of COMP neo-epitope (lg/mL) in five
horses after short-term exercise. Blood samples were taken at rest 1), after
warm-up 2), before and after interval number four (time points 3 and 4), before
and after interval number five (time points 5 and 6) and 15, 20, 30, 40 and
50 min after the last exercise interval (time points 7, 8, 9, 10 and 11). A final
blood sample (time point 12) was collected before feeding the same day (1–4.5 h
post-exercise).
676 Equine Veterinary Journal 51 (2019) 674–680 © 2019 The Authors. Equine Veterinary Journal published by John Wiley & Sons Ltd on behalf of EVJ Ltd.
Serum concentrations of a COMP neo-epitope in horses S. Ekman et al.
both normal and pathologic matrix degradation and synthesis as well as
overall inflammation. Available assays cannot detect early disease in
individual animals, although they might indicate joint disease in
populations. It is crucial that a biomarker can distinguish normal cartilage
metabolism from pathologic fragmentation to identify joint pathology.
Successful diagnostic assays will enable the detection of early OA and its
progression on an individual level. Additionally, diagnosing acute lameness
and monitoring treatment effects would be of great value. These assays
can be used to adapt new physiological training programmes and reduce
animal suffering.
This study was the first to show that increased serum concentrations of
a unique COMP neo-epitope are associated with acute lameness in horses.
The ROC analysis assessing diagnostic and predictive accuracy showed
that the test discriminates clearly between healthy and lame horses. In vivo
results corresponded with a previous inflammatory explant model, in
which the cleavage site of COMP increased after IL-1b stimulation [19].
Similar results were obtained for horses with chronic stages of OA, with
increased concentrations of other COMP fragments in the synovial fluid,
whereas no significant difference was found for serum levels of these
COMP fragments in horses with OA compared to the levels in healthy
horses [10], probably reflecting normal and pathologic cartilage turnover.
Using sandwich ELISA based on a combination of unlabelled 2A11 and
biotinylated 11 F10 monoclonal antibodies (mAbs), a significant increase in
synovial fluid COMP concentrations was identified in horses with OA [10].
However, mAbs that bound smaller COMP fragments did not show any
change in serum and synovial concentrations in horses with experimentally
induced osteochondral fractures; whereas, the concentration of COMP
fragments was significantly higher in horses that developed osteophytes,
suggesting increased COMP concentrations during severe chronic stages
[11]. In contrast, our study suggested that the unique COMP neo-epitope
(with N-terminal cleavage site SGPTH), is a potential biomarker of acute
lameness in individual horses.
Immunohistochemical staining of the COMP neo-epitope in articular
cartilage with mild and moderate destruction showed a different pattern,
and no staining could be seen in normal articular cartilage. The cartilage
with cleft formations had more prominent staining compared to that in the
focally superficial fibrillated cartilage. The COMP neo-epitope staining
pattern in articular cartilage with lesions compatible with OA supports the
higher serum concentrations found in acutely lame horses.
The STB horses used for circadian and short-term exercise
measurements were subjected to conventional race training. These horses
were not clinically examined with flexion tests before entering the study.
Hence, one can speculate that the higher serum concentrations (mean 2–
3 lg/mL) compared to those in healthy horses (mean 0.84 lg/mL), might
reflect horses with chronic joint pathology; however, they were not
obviously lame upon sampling.
Our results show that serum COMP neo-epitope concentrations are not
influenced by time of day (circadian), short-term exercise or age. However,
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Fig 2: Mean (s.d.) serum concentration of COMP neo-epitope (lg/mL) in five horses during 24 h box rest. Blood samples were taken every hour for 24 h to determine
the resting profile. Additional blood samples were taken every 15 min for 1 h after the 17:30 and 05:30 meals.
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Fig 3: Serum concentrations of COMP neo-epitope (lg/mL) related to age in 32
horses. The correlation coefficient for age and serum concentration was
r = 0.0013 and the corresponding P value (0.99) indicated no correlation
between these parameters.
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Fig 4: Serum concentration of COMP neo-epitope (lg/mL) in independent
samples from healthy horses (n = 41) and those with acute lameness (n = 71).
Significantly increased COMP neo-epitope concentrations were found in horses
with acute lameness (mean  s.d., 5.24  1.83 lg/mL) compared to those in
healthy horses (0.84  0.38 lg/mL; P<0.001).
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there was a statistically significant decrease in concentrations after short-
term speed training 3, which could be explained by reduced plasma
volumes [21] as one may speculate that the COMP fragment can leave the
circulation due to the high hydrostatic pressure developed during high
intensity exercise. However, after 20 min post-exercise, values returned to
baseline. Studies contradicting our results have been presented; serum
concentrations of total and fragmented COMP in horses were found to
decrease with age [22] and OA [23], and to increase after exercise [24] and
in race horses with OA subjected to long-term training (5 years) [25]. Higher
urine total COMP concentrations were also found in horses with septic and
aseptic arthritis [26]. Further, no changes in synovial fluid total COMP
concentrations were found following arthroscopic removal of
osteochondral fragments in horses [27]. However, in contrast to the
present study, these assays measure COMP fragmentation from normal
turnover and pathologic destruction, explaining the reported different
results. COMP measurements using different assays are not consistent;
probably due to the use of antibodies that recognise internal/native
epitopes and hence detect both intact and fragmented forms of the
protein.
We chose Icelandic horses as control horses, since this breed is known
to have OA in the distal tarsal joints (spavin) [28], but rarely in other joints
[29]. The horses included had normal radiographs of the tarsal joints and
were clinically fit for the riding test. Serum concentrations of COMP neo-
epitope were low in these horses compared to those in horses with
clinically acute lameness.
Other COMP neo-epitopes have been identified in synovial fluid from
patients with different joint diseases; patients with acute knee pain had the
highest serum concentrations of these neo-epitopes, as compared to those
in patients with rheumatoid arthritis or OA [30]. The cytokine IL-1b has
been shown to enhance the cleavage and release of COMP from tendon
explants [31], with fragments being present in the early stage of tendon
disease. The authors concluded that these fragments can ‘provide a
platform for the development of neo-epitope assays specific to injury stage
for tendon disease’.
The COMP neo-epitope quantified in the current study was also
identified in an IL-1b-stimulated equine explant model [19] and was already
degraded at day 3 of cytokine stimulation. Its concentration was found to
increase in synovial fluid [16] and sera from horses presenting with acute
lameness. Furthermore, immunolabelling detected the COMP neo-epitope
in the cytoplasm of chondrocytes surrounding the fibrillation of the mild
and severe OA articular cartilage, but not in chondrocytes of normal
articular cartilage. Its presence in superficial and deep fraying of articular
cartilage and the increase in serum and synovial concentrations [16] in
horses with acute lameness suggest that this neo-epitope has a role in the
early and acute stages of equine OA. Hence, unique COMP fragmentation
related to cytokine stimulation could be valuable for monitoring the stages
of connective tissue damage.
Our results also show that short-term training does not influence serum
concentrations of this unique COMP neo-epitope. This is in accordance
with results in humans, wherein no changes in serum COMP
concentrations were observed after 1 h of running [32] or during a follow-
up of long-term training in volleyball athletes [33].
Easy-to-use biomarker assays that can diagnose the early painful OA
stage would be of great value, especially in young racehorses. If early
joint disease is identified, it will be possible to change the training
programme and treat the joint inflammation, which could prevent OA
progression.
In conclusion, the present study showed that serum concentrations of a
unique COMP neo-epitope in horses represent a potential biomarker for
acute joint disease that is not affected by age, short-term training or
circadian rhythms during rest. The production of monoclonal antibodies
has been initiated to establish a sandwich ELISA. Further studies must be
performed using a larger population of healthy and diseased horses, and
these reference values will provide the basis for developing a diagnostic
tool. Additional to future studies we would investigate whether different
joints can influence the levels.
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